Anixa Biosciences Secures First Korean Patent for Breast Cancer Vaccine, Extending Protection to 2040
ANIX sits 20% above its 52-week low of $2.32 on elevated volume (7.0× avg).
Summary
Anixa Biosciences secured its first Korean patent for its breast cancer vaccine, extending exclusive protection in South Korea through 2040. This builds on positive Phase 1 clinical trial results for the vaccine announced in April and a Canadian patent allowance for its ovarian cancer vaccine in June. Expanding intellectual property into key international markets is a critical step for future commercialization and potential partnerships, especially as the company progresses clinical development.
At the time of this announcement, ANIX was trading at $2.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.9M. The 52-week trading range was $2.32 to $5.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.